This prespecified secondary analysis of the phase 3 VALOR RCT evaluated once-daily brepocitinib (30 mg or 15 mg) vs. placebo over 52 weeks in 241 adults with active dermatomyositis, focusing on cutaneous disease activity (CDASI-A), itch (PP-NRS), skin-related QOL (Skindex-16), and remission-level skin endpoints.
Brepocitinib 30 mg was superior to placebo from week 4 onward: mean CDASI-A change −6.4 vs −3.5 (difference −3.0; 95% CI −4.6 to −1.4; P<.001); itch remission (PP-NRS ≤1) achieved in 38.3% vs 19.0%; and among those with moderate-to-severe skin disease, functional skin remission (CDASI-A ≤5) in 43.5% vs 20.8% at week 52.
Secondary/exploratory analysis of a trial powered for broader endpoints, not skin-specific outcomes; the 15 mg dose results are not detailed in the abstract, limiting dose-comparison conclusions; follow-up was 52 weeks with no data beyond that timeframe.
Brepocitinib 30 mg once daily produced rapid (by week 4), sustained, and remission-level skin control in dermatomyositis — consider it a strong oral option for patients with active cutaneous disease. The safety profile aligns with other approved JAK/TYK2 inhibitors, so standard monitoring applies.
